← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Ipamorelin × GHRP-2 × 2 of 4 selected View comparison

Ipamorelin

GH secretagogue

Remove
VS

GHRP-2

GH-releasing peptide / GH secretagogue

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target IpamorelinGHRP-2
✓ ✓

Pathway Map

This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.

Ipamorelin / GHRP-2 → GHSR1a (direct target) → Pituitary/hypothalamic signalling → GH Steps after GHSR1a are the general ghrelin-pathway cascade, not a compound-specific demonstrated effect.

What These Compounds Share

Shared direct targets (all selected compounds)
GHSR1a
Shared research line

All selected compounds are catalogued under Peak.

Shared pathway tags
GHSR1aGH SecretagogueGH
Shared research areas
GH secretion

Key Differences

Ipamorelin Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. Acts through GHSR rather than the GHRH receptor.
GHRP-2 Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. A ghrelin-mimetic GH secretagogue with appetite-related pharmacology.

Compound Detail

Ipamorelin
What is it?
A peptide that mimics the "hunger hormone" signal your body uses to trigger growth hormone release.
What are people researching/using it for?
Studied for stimulating natural growth hormone release.
Other uses being trialed
General GH-axis research, often studied alongside GHRH-type compounds
Worth knowing
Human studies in the literature include IV administration; this is descriptive of research routes only, not administration guidance.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Ghrelin/GH-secretagogue receptor agonism that stimulates GH release.
Pentapeptide · 5 amino acids · Synthetic
Primary Targets & Biological System
Ghrelin / GH-secretagogue signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A pentapeptide that activates the ghrelin receptor (GHSR1a) -- the same receptor the hunger hormone ghrelin normally binds -- which in the pituitary triggers growth hormone release. This is a mechanistically distinct route to GH release compared with GHRH-receptor agonists like tesamorelin or sermorelin; the two pathways can, in principle, be additive since they act through different receptors, which is part of why GHRH and GHRP/ghrelin-pathway compounds are often discussed together in GH-axis research. Ipamorelin is generally described in the literature as more selective for GH release, with comparatively less effect on other pituitary hormones than some earlier ghrelin-pathway secretagogues.
Research Areas
GH secretionPituitary physiologyEndocrine researchGhrelin receptor pharmacology
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Approximately 2 hours
Human terminal half-life reported in human PK/PD research.
Research Routes
Subcutaneous (research contexts), Intravenous (human PK/PD research) (descriptive only — not administration or dosing guidance)
Key Differentiator
Acts through GHSR rather than the GHRH receptor.
Considerations
Research Limitations
Human studies in the literature include IV administration; this is descriptive of research routes only, not administration guidance.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Ipamorelin · A$74.95 A$89.95
Browse products →
View Research Sources (1) →
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Human Human · Healthy volunteers · Intravenous (PK/PD study) · PMID 10496658 · DOI 10.1023/A:1018955126402

Reports terminal half-life ~2h, clearance 0.078 L/h/kg, Vss 0.22 L/kg.

Supports: human_half_life

GHRP-2
What is it?
Similar to ipamorelin -- a peptide that triggers growth hormone release through the hunger-hormone pathway.
What are people researching/using it for?
Studied for growth hormone release.
Other uses being trialed
Appetite-related research, since it shares a receptor with the hunger hormone ghrelin
Worth knowing
An exact half-life value is only shown with a direct, reliable human source. Its appetite-stimulating effect is directly demonstrated in healthy men (see sources); this does not by itself establish benefit in cachexia/wasting patients, a distinct and more vulnerable population.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A synthetic ghrelin-receptor agonist stimulating GH secretion and influencing appetite-related signalling.
Peptide · Synthetic
Primary Targets & Biological System
Ghrelin / GH-secretagogue signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Like ipamorelin, GHRP-2 activates the ghrelin receptor (GHSR1a) to stimulate pituitary growth hormone release. Because this is the same receptor ghrelin itself uses to signal hunger, GHRP-2 has also been associated with appetite-stimulating effects in research -- a secondary effect not necessarily shared to the same degree by other GHSR1a agonists, and a meaningful practical distinction from GHRH-pathway compounds like tesamorelin, which aren't known to directly affect appetite through this mechanism.
Research Areas
GH secretionAppetiteGhrelin biologyPituitary/endocrine research
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Not displayed without a direct reliable human source.
Research Routes
Subcutaneous (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
A ghrelin-mimetic GH secretagogue with appetite-related pharmacology.
Considerations
Research Limitations
An exact half-life value is only shown with a direct, reliable human source. Its appetite-stimulating effect is directly demonstrated in healthy men (see sources); this does not by itself establish benefit in cachexia/wasting patients, a distinct and more vulnerable population.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Cancer-related appetite loss (cachexia)
A controlled human study found subcutaneous GHRP-2 infusion increased food intake by 35.9% versus saline in 7 healthy lean men, confirming the ghrelin/GHSR1a-mediated appetite effect is real in humans, not just theoretical. Research applying this specifically to cancer-related cachexia/wasting patients (a different, more vulnerable population) is still limited.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
GHRP-2 · A$69.95 A$89.95
Browse products →
View Research Sources (1) →
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men
Journal of Clinical Endocrinology & Metabolism, 2005 · Human Human · 7 lean, healthy men · Subcutaneous infusion · PMID 15699539 · DOI 10.1210/jc.2004-1719

SC GHRP-2 infusion (1 mcg/kg/h, 270 min) increased ad libitum food intake by 35.9±10.9% vs saline (P=0.008); GH AUC also significantly increased (P=0.003). Direct human confirmation of the ghrelin/GHSR1a-mediated appetite effect.

Supports: mechanism_summary, experimental_research

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.